Renewal opportunity for ongoing NINDS-supported clinical trials needing more time and resources via U01 cooperative agreements.
Funder: National Institutes of Health
Due Dates: March 5, 2027 (Application) | July 5, 2027 (Application) | November 5, 2027 (Application)
Funding Amounts: No budget cap; requests must reflect actual completion needs; maximum project period of 5 years
Summary: Supports renewals of eligible existing NINDS clinical trial U01 awards needing additional time and resources to complete their originally approved trials.
Key Information: Limited to existing awards from five specified funding announcements; applications with new aims are returned without review.
The National Institute of Neurological Disorders and Stroke (NINDS), part of NIH, offers this limited competition for renewal of existing clinical trial cooperative agreement awards. PAR-25-149 provides additional time and resources to complete active trials originally funded through specified NINDS Efficacy Clinical Trials or NIH StrokeNet announcements. Requests must be limited to completing the trial as originally proposed and approved, rather than adding new aims.
The program supports completion of research that remains scientifically relevant and capable of advancing neurological care or knowledge. Applicants must explain trial progress, reasons for delays, corrective actions, and the feasibility of completion during the renewal period. Awards use the U01 cooperative agreement mechanism, with substantial NINDS scientific and programmatic involvement and oversight by an NINDS-appointed Data and Safety Monitoring Board.